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Abstract
Background and purpose
Excess insulin resistance is considered the predominant pathophysiological mechanism in
obese women who develop gestational diabetes (GDM). We hypothesised that obese
women requiring differing treatment modalities for GDM may have diverse underlying meta-
bolic pathways.
Methods
In this secondary analysis of the UK pregnancies Better Eating and Activity Trial (UPBEAT)
we studied women from the control arm with complete biochemical data at three gestational
time points; at 15–18+6 and 27–28+6 weeks (before treatment), and 34–36+0 weeks (after
treatment). A total of 89 analytes were measured (plasma/serum) using a targeted nuclear
magnetic resonance (NMR) platform and conventional assays. We used linear regression
with appropriate adjustment to model metabolite concentration, stratified by treatment
group.
Main findings
300 women (median BMI 35kg/m2; inter quartile range 32.8–38.2) were studied. 71 devel-
oped GDM; 28 received dietary treatment only, 20 metformin, and 23 received insulin. Prior
to the initiation of treatment, multiple metabolites differed (p<0.05) between the diet and
insulin-treated groups, especially very large density lipoprotein (VLDL) and high density lipo-
protein (HDL) subclasses and constituents, with some differences maintained at 34–36
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weeks’ gestation despite treatment. Gestational lipid profiles of the diet treatment group
were indicative of a lower insulin resistance profile, when compared to both insulin-treated
women and those without GDM. At 28 weeks’ the diet treatment group had lower plasma
fasting glucose and insulin than women treated with insulin, yet similar to those without
GDM, consistent with a glycaemic mechanism independent of insulin resistance.
Conclusions/Interpretation
This exploratory study suggests that GDM pathophysiological processes may differ
amongst obese women who require different treatment modalities to achieve glucose con-
trol and can be revealed using metabolic profiling.
Introduction
For most healthcare professionals and pregnant women, gestational diabetes mellitus (GDM)
diagnosis is understood to be a binary categorisation of hyperglycaemia versus normoglycae-
mia. This is despite a well-established linear increase in risk of adverse outcomes across the
glycaemic spectrum [1], and the potential for pathophysiological heterogeneity of GDM with
diverse maternal and offspring outcomes [2].
Hyperglycaemia in pregnancy is widely accepted to result from an imbalance between ris-
ing insulin resistance and inadequate insulin secretion, yet specific mechanisms likely differ
between, and amongst phenotypic groups. Amongst obese women for example, excessive insu-
lin resistance is considered to be the predominant pathophysiological mechanism, whereas
insulin secretory defects may predominate in lean women with GDM [2–5]. This distinction
was corroborated in a recent study in which biochemical and clinical heterogeneity were
described in women with GDM, classified as GDM with an insulin secretion defect, GDM
with an insulin sensitivity defect, and mixed defects. The authors reported that women with a
predominant insulin sensitivity defect were those with a higher BMI [2].
Health care professionals appreciate that women with GDM will require different treatment
modalities according to their ability to control glycaemia. While this may reflect disease sever-
ity, maternal lifestyle or adherence to treatment, diverse underlying disease processes may also
be contributory. Improved understanding of the pathophysiology could facilitate management
through delineation of subtypes of GDM, enabling targeted therapy [6].
We have previously shown that obese women with GDM have differing metabolic profiles
from obese women without GDM and that this is evident prior to diagnosis [7]. Using the
same dataset, we have hypothesised that the measured analytes might further distinguish
between groups necessitating diverse treatment approaches to achieve glucose control. Metab-
olite phenotypes were therefore compared between women allocated to different GDM treat-
ment strategies in a proof of principle exploratory study. To our knowledge, there has been no
previous attempt to define subgroups according to measured analytes, and by treatment
strategy.
Materials and methods
Study design
This prospective cohort study was a secondary analysis utilising data from the UK Pregnancies
Better Eating and Activity Trial (UPBEAT, ISRCTN 89971375), a multicentre RCT of a
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complex dietary and physical activity intervention designed to prevent GDM in obese women
and reduce the incidence of LGA infants [8]. Women with a pre-existing diagnosis of essential
hypertension, diabetes, coeliac disease, thyroid disease, renal disease, systemic lupus erythema-
tosus, antiphospholipid syndrome, sickle-cell disease, thalassaemia, current psychosis, or a
current prescription of metformin were excluded. The UPBEAT trial (recruitment 2009 to
2014), included 1555 women; they were >16 years of age, had a Body Mass Index (BMI)
�30kg/m2 and a singleton pregnancy. Women were randomised between 15+0 and 18+6
weeks’ gestation to either a behavioural intervention superimposed on standard antenatal care
or standard antenatal care. All aspects of the trial, including the analyses for the present study
were approved by the NHS Research Ethics Committee (UK Integrated Research Application
System; reference 09/H0802/5) and all participants, including women aged 16 and 17 using
Fraser guidelines, provided informed written consent [8].
Participants
A complete-case analysis was undertaken and included all women from the control arm of
UPBEAT who had undertaken a diagnostic Oral Glucose Tolerance Test (OGTT), with docu-
mented GDM treatment modality and complete biochemical data at trial entry, at the time of
GDM testing and in late pregnancy (n = 300). Women were excluded if these criteria were not
met, if GDM was diagnosed by local thresholds but did not fulfil diagnostic criteria according
to the trial protocol (n = 3), or who fulfilled the trial protocol diagnostic criteria, but not local
criteria for GDM diagnosis (n = 23).
Procedures
Sociodemographic and clinical data, and non-fasting blood samples were collected at time
point 1 (15–18+6 gestational weeks’; mean 17+0). The trial protocol specified that an OGTT
should be performed between 27 and 28+6 gestational weeks’, however a clinically pragmatic
approach has been adopted for the purposes of this study with inclusion of OGTTs undertaken
between 23+3 and 29+6 (mean 27+5). A research blood sample was collected at the time of the
OGTT fasting sample (time point 2). Diagnosis of GDM was according to International Asso-
ciation of Diabetes and Pregnancy Study Groups (IADPSG) criteria (fasting glucose�5.1
mmol/l, 1 hr�10.0 mmol/l, 2 hr�8.5 mmol/l) in response to an oral 75g glucose load [9]. A
non-fasting blood sample was collected at time point 3 (34–36+0 gestational weeks’, mean
34+6). Pregnancy outcome data was recorded shortly after delivery.
The main outcome of interest was GDM treatment modality following diagnosis. Women
were subcategorised into: No-GDM; GDM Diet Group (treated with diet only); GDM Metfor-
min Group (treated with metformin); GDM Insulin Group (treated with insulin alone or met-
formin plus insulin). Study centres reported that GDM treatment most frequently began with
dietary advice, followed by the addition of metformin and then insulin if control was not
achieved, either due to glycaemic severity or poor compliance. Modality was recorded as the
treatment at the time of delivery.
Metabolic profiling
Analytes were measured in plasma and serum samples using a combination of NMR spectros-
copy and conventional assays. A high-throughput targeted NMR metabolomic platform was
utilised (http://www.computationalmedicine.fi/platform). The quantitative NMR measures
include numerous lipid species, fatty acids, amino acids, and markers of glucose homeostasis
and has been used widely in population-based studies of insulin resistance and metabolic dis-
ease [10–14]. The methodology has been described previously [15]. Analytes measured using
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conventional laboratory platforms (S1 Table) included glucose homeostasis markers, sex hor-
mone binding globulin (SHBG), gamma glutamyl transferase (gGT) and adiponectin. For the
purposes of this study and to restrict multiple comparisons, only those analytes identified pre-
viously as different between women with GDM and women without GDM at the time of diag-
nosis (time point 2) [7] were explored. A total of 89 analytes, 83 from the NMR metabolome,
were evaluated.
Statistical analysis
The distribution of data for each analyte was checked for normality and those with non-
parametric distribution log-transformed. Relationships between the concentration of variables
and gestational age were explored; none required transformation.
Analyte data at time points 1, 2 and 3 were compared by treatment modality group by mul-
tivariate regression analyses, with No-GDM as the baseline group for comparison. Standard
Deviation (SD) differences between each treatment category and No-GDM are reported to
enable comparison between analytes with differing units of measurement. Exploratory analy-
ses compared women treated by insulin with those treated by diet.
An a priori decision based on known associations identified age and BMI as confounders
for the multivariate analyses. Each regression was clustered by centre.
Pregnancy outcomes between GDM treatment groups were compared using either one-
way ANOVA or the Kruskal Wallis test depending on the distribution of data.
Due to small numbers and the exploratory nature of this investigation, no sensitivity analy-
ses were undertaken, although differences between women with GDM included and those
excluded, were investigated. No formal correction for multiple testing was undertaken and sta-
tistical significance was assumed at a p value <0.05.
Statistical analysis was performed using Stata software, version 14.0 (StataCorp LP, College
Station, Texas).
Results
Of the 664 women in the control arm of UPBEAT, 300 with complete biochemical data were
included (median BMI 35 kg/m2, Interquartile range (IQR) 32.8–38.2). Of these, 229 did not
develop GDM (No-GDM group); 71 (24%) developed GDM, of whom 28 (39%) were treated
by diet (Diet Group); 20 (28%) with metformin (Metformin Group); and 23 (32%) with insulin
(Insulin Group; 9 insulin alone, 13 insulin plus metformin) (S1 Fig).
Participant characteristics and pregnancy outcome by treatment modality are summarised
in Table 1. Comparison between women with GDM included in this study compared to those
excluded are shown in S2 Table.
The analyte profiles are illustrated by a representative subset (n = 22) of different metabolite
groups (Figs 1–3). Metabolite absolute values at each time point for this subset are shown in
S3–S5 Tables. Absolute values and graphical representation for all measured analytes are avail-
able on request.
Analytes by treatment modality
Diet, metformin and insulin groups. Time point 1; 10 weeks before diagnosis/treatment
(random blood sample). At least 10 weeks before OGTT and initiation of treatment, differences
between the metabolic profiles of treatment modality groups were identified (Fig 1, S3 Table).
Greater concentrations of total lipids within VLDL were observed in the pharmacologically
treated groups (Metformin and Insulin Groups), whereas women in the Diet Group demon-
strated VLDL lipid concentrations similar to those who did not develop GDM. The Diet group
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Table 1. Maternal clinical factors and pregnancy outcome by treatment modality in women with and without GDM.
No GDM GDM
(n = 229) Diet (n = 28) Metformin (n = 20) Insulin (n = 23)
mean (SD)/ median (IQR) mean (SD) / median (IQR) mean (SD) / median (IQR) mean (SD) / median (IQR)
n (%) n (%) n (%) n (%)
Maternal factors (collected time point 1)
Age (years) 30.5 (5.5) 32.7 (4.8) 31.6 (5.9) 32.2 (5.1)
Blood pressure (mmHg)
Systolic 118.7 (10.8) 123.5 (12.5) 119.2 (7.3) 118.8 (8.3)
Diastolic 72.7 (7.7) 75.3 (7.8) 72.1 (5.8) 72.8 (6.0)
BMI (kg/m2) 34.8 (32.7–37.8) 35 (32.4–39.5) 36.1 (33.5–39.9) 37.4 (34.6–40)
Ethnicity
African 20 (8.7) 9 (32.1) 3 (15) 2 (8.7)
African Caribbean 12 (5.2) 4 (14.3) 1 (5) 1 (4.3)
South Asian 17 (7.4) 1 (3.6) 2 (10) 1 (4.3)
European 161 (70.3) 12 (42.9) 12 (60) 16 (69.6)
Other 19 (8.3) 2 (7.1) 2 (10) 3 (13)
Parity
Nulliparous 111 (48.5) 10 (35.7) 11 (55) 13 (56.5)
Current Smoking 14 (6.1) 1 (3.6) 1 (5) 2 (8.7)
Centre
St Thomas’ Hospital 62 (27.1) 19 (67.9) 12 (60) 8 (34.8)
Newcastle 43 (18.8) 4 (14.3) 4 (20) 0 (0)
Glasgow 67 (29.3) 2 (7.1) 3 (15) 11 (47.8)
Manchester 24 (10.5) 1 (3.6) 0 (0) 2 (8.7)
Bradford 12 (5.2) 0 (0) 0 (0) 1 (4.3)
St Georges Hospital 21 (9.2) 2 (7.1) 1 (5) 1 (4.3)
OGTT results
Fasting glucose 4.5 (0.3) 4.9 (0.5) 5.4 (0.6) 5.4 (0.6)
1hr glucose 7.4 (1.4) 9.7 (1.8) 11.4 (1.5) 10.7 (1.8)
2hr glucose 5.5 (1.1) 6.8 (1.2) 7.5 (1.2) 7.4 (1.8)
Gestational age (weeks)
Time point 1 16.9 (1.1) 17.2 (1.1) 17.1 (1.0) 17.5 (0.9)
Time point 2 27.7 (0.7) 27.8 (0.6) 27.9 (0.6) 27.8 (0.5)
Time point 3 34.9 (0.8) 34.7 (0.5) 34.7 (0.5) 34.5 (0.5)
Pregnancy outcomes
Preeclampsia 8 (3.5) 2 (7.1) 1 (5) 2 (9.1)
PPH 34 (14.8) 5 (17.9) 2 (10) 6 (26.1)
Weight change (Kg)� 2.7 (2.1) 1.0 (2.4) -1.0 (2.0) 1.0 (2.6)
NICU 7 (3.1) 4 (14.3) 0 (0) 3 (13)
Apgar <7 at 1 min 3 (1.3) 1 (3.6) 0 (0) 1 (4.3)
Preterm birth 4 (1.7) 1 (3.6) 1 (5) 0 (0)
CS all 77 (33.6) 11 (39.3) 6 (30) 11 (47.8)
CS emergency 45 (19.7) 7 (25) 4 (20) 5 (21.7)
GA at delivery 40.6 (39.3–41.4) 39.8 (38.8–40.6) 38.6 (38.1–39.2) 38.3 (37.9–38.6)
Birthweight (g) 3545.4 (487.9) 3386.4 (556.1) 3288.5 (360.1) 3314.6 (379.4)
SGA (customised centile) 23 (10) 5 (17.9) 1 (5) 1 (4.3)
BW (customised centile) 44.1 (22.8–68.1) 51.5 (20.9–76.2) 53.2 (30.3–76.3) 64.1 (40.7–81.5)
(Continued)
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had larger large density lipoprotein (LDL) and HDL particles compared to No-GDM women,
whereas the pharmacologically treated groups had larger VLDL particles. Women in the Met-
formin Group had lower polyunsaturated fatty acid: total fatty acid ratios (PUFA:TFA) and
Table 1. (Continued)
No GDM GDM
(n = 229) Diet (n = 28) Metformin (n = 20) Insulin (n = 23)
mean (SD)/ median (IQR) mean (SD) / median (IQR) mean (SD) / median (IQR) mean (SD) / median (IQR)
n (%) n (%) n (%) n (%)
LGA (customised) 15 (6.6) 3 (10.7) 1 (5) 3 (13)
�weight change between time point 2 and 3, GDM gestational diabetes, SD standard deviation, IQR interquartile range, OGTT oral glucose tolerance test, PPH post-
partum haemorrhage, NICU neonatal intensive care, CS caesarean section, GA gestational age, SGA small for gestational age, BW birthweight, LGA large for gestational
age. Time point 1—mean 17+0 weeks, time point 2—mean 27+5 weeks, time point 3—mean 34+6 weeks, missing data: systolic and diastolic blood pressure—5, Apgar—2,
1hr glucose—16
https://doi.org/10.1371/journal.pone.0230658.t001
Fig 1. Metabolite SD difference between GDM treatment groups compared to No-GDM women at time point 1, 10 weeks before diagnosis/treatment (mean 17+0
weeks’). Data points show the standard deviation (SD) difference between treatment group and No-GDM women. Positive differences compared to No-GDM are shown
to the right, negative to the left. PUFA:TFA polyunsaturated fatty acids to total fatty acid ratio, MUFA:TFA monounsaturated fatty acid to total fatty acid ratio, SFA:TFA
saturated fatty acid to total fatty acid ratio.
https://doi.org/10.1371/journal.pone.0230658.g001
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higher saturated fatty acid:total fatty acid ratios (SFA:TFA) than No-GDM women. The
branched-chain amino acid isoleucine was higher in women in the Metformin Group than in
women without GDM. Non-fasting glucose was higher than No-GDM in Diet, Metformin and
Insulin Groups. Amongst the women eventually treated with insulin, the non-fasting insulin
concentration varied widely and was no different from No-GDM women. This contrasted
with a significantly higher insulin pre-treatment concentration in the Diet and Metformin
Groups than in women without GDM (Fig 1)
Time point 2; at OGTT (fasting blood sample). At time point 2, the time of GDM diagnosis
but prior to treatment initiation, divergence in analytes between the groups had widened (Fig
2, S4 Table). The Insulin Group had higher concentrations of total lipids in most VLDL sub-
classes than women without GDM. A similar trend was seen in the Metformin Group.
Women in the Diet Group, in contrast, had lower total lipids in small VLDL, higher total lipids
in very large and large HDL subclasses and lower VLDL cholesterols compared to women
without GDM. VLDL particle size, total triglycerides and triglycerides in both VLDL and HDL
were greater in the Insulin Group than women without GDM. In the Diet Group HDL and LDL
particle size were greater. The PUFA:TFA ratio was lower in both the metformin and insulin
Fig 2. Metabolite SD difference between GDM treatment groups compared to No-GDM women at time point 2, at time of OGTT (mean 27+5 weeks’). Data points
show the standard deviation (SD) difference between treatment group and No-GDM women. Positive differences compared to No-GDM are shown to the right, negative
to the left. PUFA:TFA polyunsaturated fatty acids to total fatty acid ratio, MUFA:TFA monounsaturated fatty acid to total fatty acid ratio, SFA:TFA saturated fatty acid to
total fatty acid ratio.
https://doi.org/10.1371/journal.pone.0230658.g002
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treated groups than No-GDM women. Monounsaturated fatty acid:total fatty acid ratios (MUFA:
TFA) and SFA:TFA were greater in the Metformin and Insulin Groups respectively. Isoleucine
was higher in the women ultimately treated by metformin. In this fasting sample, glucose and
insulin were significantly higher only in the Metformin and Insulin Groups (Fig 2, S4 Table).
Time point 3; following treatment (random blood sample). The mean duration of treatment,
from diagnosis to blood draw at time point 3, was 7.1 weeks’ (range 4.9–12, SD 0.9). As only
final treatment modality was recorded, the number of weeks on this treatment was unknown.
Differences in lipid species and other analytes observed at the time of the OGTT between Diet
and No-GDM groups remained evident after treatment, with an additional greater difference
in total VLDL lipids between these groups at the later time point. Similar trends were also
maintained between the Insulin and No-GDM Groups, although treatment was associated
with convergence towards the No-GDM profile. ‘Normalisation’ towards the No-GDM group
was evident following treatment with metformin (Metformin Group), including glucose and
insulin, with differences remaining only for total triglycerides and triglycerides in HDL, and
alanine (Fig 3).
Fig 3. Metabolite SD difference between GDM treatment groups compared to No-GDM women at time point 3, following treatment (mean 34+6 weeks’). Data
points show the standard deviation (SD) difference between treatment group and No-GDM women. Positive differences compared to No-GDM are shown to the right,
negative to the left. PUFA:TFA polyunsaturated fatty acids to total fatty acid ratio, MUFA:TFA monounsaturated fatty acid to total fatty acid ratio, SFA:TFA saturated fatty
acid to total fatty acid ratio.
https://doi.org/10.1371/journal.pone.0230658.g003
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Gestational profile of glucose and total triglycerides in Insulin versus Diet Groups. Figs 4 and
5 illustrate the gestational profile of total triglyceride and glucose concentrations of No-GDM,
Diet and Insulin Groups. At time points 2 and 3 triglycerides were greater in the Insulin
Group compared to the Diet-treated women, with no difference between the Diet Group and
women without GDM. At time point 2 (fasting sample), glucose concentration in the Insulin
Group was higher than both women treated with diet and those without GDM, with no differ-
ence between these latter groups.
Discussion
To our knowledge there has been no previous attempt to assess the metabolic profile in GDM
in obese women according to the three conventional modalities of treatment; diet, metformin
and insulin. Whilst, as might be anticipated, treatment led towards convergence of analytes
towards the ‘norm’, we also identified differing analyte profiles early in pregnancy amongst
women, according to their eventual treatment regime.
Comparison between treatment groups
The rationale for treatment of GDM with diet or a pharmacological approach is generally
based on severity of hyperglycaemia, but we suggest that these clinical practices may be unin-
tentionally predicated, at least in part, by aetiological differences. Trends in analyte concentra-
tions were most evident from early gestation between women in whom GDM was treated with
Fig 4. Total triglyceride measurements in diet treated, insulin treated and No-GDM women at 3 gestational time points across
pregnancy. time point 2 (mean 27+5 weeks’) was fasting. 95% CI, not adjusted. � p value<0.05.
https://doi.org/10.1371/journal.pone.0230658.g004
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diet and those treated with insulin; throughout pregnancy, women ultimately treated with insu-
lin exhibited a more insulin resistant profile, whereas women whose glycaemia was ultimately
controlled by diet demonstrated a markedly non-insulin resistant profile which could indicate a
different pathway to GDM, possibly through insufficient secretion of insulin.
The gestational profile of insulin resistance identified from early pregnancy onwards in the
Insulin and to a lesser degree, the Metformin Groups, as defined by the NMR spectrum, also
included higher lipid constituents of VLDL subclasses, lower HDL constituents and smaller
LDL particle size, a profile described previously in non-pregnant insulin resistant subjects
[16–18]. Of potential relevance, an ‘Insulin Resistance Score’ based on similar indices mea-
sured by NMR is now commercially available for type 2 diabetes mellitus (T2DM) risk assess-
ment in non-pregnant individuals [19] and a similar scoring system could be envisaged for
determining GDM risk.
Similarly, the fatty acid and amino acid profiles characteristic of insulin resistance, as
observed in the women with GDM, have been identified previously in non-pregnant popula-
tions, particularly higher monounsaturated and saturated fatty acids, and branched-chain
amino acids [13, 20].
Women treated for GDM v women without GDM
When comparing the treatment groups to women without GDM, differences in metabolite
profiles were also evident from the earliest point of measurement, many weeks before treat-
ment; the Metformin and Insulin Groups already demonstrating an ‘unfavourable’, more insu-
lin resistant profile, incorporating amongst other markers, higher total lipids in VLDL
Fig 5. Glucose measurements in diet treated, insulin treated, and No-GDM women at 3 gestational time points across
pregnancy. time point 2 (mean 27+5 weeks’) was fasting. 95% CI, not adjusted. � p value<0.05.
https://doi.org/10.1371/journal.pone.0230658.g005
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subclasses and larger VLDL particle size. Women ultimately treated with diet did not share
these characteristics; total lipids in VLDLs were similar in concentration to No-GDM women,
and LDL and HDL particles were larger. As expected, all three groups exhibited higher glucose
concentrations than women without GDM. At the time of GDM diagnosis, the divergence in
analytes between groups was particularly striking; the Diet Group now showed a more favour-
able lipid profile than the women without GDM, in contrast to raised insulin resistance mark-
ers in the insulin-treated group. The Metformin Group showed intermediate lipid values,
although with an unfavourable fatty acid and amino acid profile. In accordance with aetiologi-
cal diversity amongst groups, women treated only with metformin, and women requiring
insulin were unable to maintain normoglycaemia on fasting (time point 2), whereas glucose
and insulin concentrations in the Diet Group were similar to women without GDM.
Different GDM subgroups of obese women?
The inference that the obese women treated with diet may represent a distinct subgroup is sup-
ported by a previous study inferring diverse pathways leading to GDM amongst BMI heteroge-
neous women. Similar differences in fasting glucose and insulin concentrations to those we
describe between diet and insulin treated groups were identified in women with GDM defined
by a poor insulin secretion profile (fasting glucose 76mg/dl; 72–79, fasting insulin 6.0μl/ml;
4.6–6.7) or those with an insulin resistant profile (90mg/dl; 81–94, 13.6μl/ml 9.9–20.5) respec-
tively [2].
The consistently ‘lower’ insulin resistant profile in the diet treated group throughout preg-
nancy and following treatment, adds strength to the case for a different aetiology between
groups, and we hypothesise that women in this study cohort whose GDM is treatable by diet
may represent a sub group with a poor insulin secretion profile. This is supported by the obser-
vation that following treatment, glucose homeostasis remained abnormal, with relative hyper-
glycaemia and hyperinsulinaemia (non-fasting). In contrast, insulin resistance markers in
women treated with metformin, converged towards those in women without GDM after treat-
ment, with additional improvements in glucose and insulin concentration. Women in the
Insulin Group did not achieve a similar degree of ‘normalisation’, but interpretation is limited
as the glycaemic control achieved is unknown.
A difference in gestational age at delivery was evident between GDM treatment groups,
likely reflecting the clinical approach to the timing of delivery between these groups. However,
despite differing underlying pathophysiological processes and potential severity of disease,
other pregnancy outcomes between treatment groups did not differ significantly (Table 1),
although this may reflect the small numbers in each group.
Strength and weaknesses
We believe there has been no previous exploration of mechanistic heterogeneity of treatment
groups using metabolic profiling amongst obese women.
This is a proof of concept study involving a subgroup analysis of a large cohort; although
women included were demographically similar to those not included, it is a potential weakness
that data may be missing not at random (MNAR) [21].
Based on a known effect of the UPBEAT intervention on metabolite profiles [22], a decision
was made a priori to explore subgroups in the control arm of the trial only. It is accepted that
this resulted in a reduction in the number of women in the GDM treatment groups, which is a
limitation of this study.
This, the first detailed description of metabolic profiles in relation to treatment in women
with GDM prompts further and more detailed investigation; confirmation of phenotypic
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subgroups as indicated by metabolic analyses is required amongst a larger patient sample, and
different ethnic subgroups. Measurement of more specific markers of insulin secretion and
sensitivity could further define pathophysiological subgroups.
The UPBEAT trial did not have a standardised protocol for GDM treatment which may
have differed between centres, although analyses were clustered by centre to minimise bias. As
GDM treatment modality was obtained following delivery, the time of initiation and cessation
of treatment was commonly not recorded. No formal correction for multiple testing was
undertaken because of the exploratory nature of the analysis and the small sample size.
In summary, targeted metabolomic analyses have suggested diverse profiles according to
treatment modality. Confirmation in larger populations is required and if validated could pro-
vide a rationale for early stratification and appropriate therapy.
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